EBR – Morgans rates the stock as Speculative Buy

Morgans feels EBR Systems has attained a key milestone by completing interim trial enrolment in SOLVE on time, which may lead to FDA submission by the first half of 2023.

The company has secured up to $50m in debt financing, which the broker sees as prudent. The target falls to $1.38 from $1.84 to reflect increased volatility and higher funding costs. The Speculative Buy rating is maintained.

Sector: Health Care Equipment & Services.


Target price is $1.38.Current Price is $0.53. Difference: $0.85 – (brackets indicate current price is over target). If EBR meets the Morgans target it will return approximately 62% (excluding dividends, fees and charges – negative figures indicate an expected loss).



About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →